Findings

What do systematic reviews say?

96 questions · 102 findings · 12 reviews

Sort:Best matchNewest Highest certainty Download CSV

No studies found 24 · 23.5%GRADE not reported 2 · 2%Very low 26 · 25.5%Low 30 · 29.4%Moderate 12 · 11.8%High 8 · 7.8%

Omega‐3 vs placebo

Frequency of crisis · sickle cell disease

The review found no eligible studies for this question.

1 finding from 1 review

Antioxidant supplementation for sickle cell disease 2024 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Omega‐3 vs placebo

Severity of pain · sickle cell disease

The review found no eligible studies for this question.

1 finding from 1 review

Antioxidant supplementation for sickle cell disease 2024 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Omega‐3 vs placebo

QoL of participants living with SCD and their caregivers · sickle cell disease

The review found no eligible studies for this question.

1 finding from 1 review

Antioxidant supplementation for sickle cell disease 2024 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Omega‐3 vs placebo

Adverse effects (any adverse effect) · sickle cell disease

It is very uncertain whether omega‐3 changes adverse effects (any adverse effect) compared with placebo (very low certainty).

1 finding from 1 review

Antioxidant supplementation for sickle cell disease 2024 · Cochrane Headline outcomes only
RR 1.05 [0.74, 1.48]
1 study · 67 participants
Very low

Omega‐3 vs placebo

Frequency of hospitalization · sickle cell disease

The review found no eligible studies for this question.

1 finding from 1 review

Antioxidant supplementation for sickle cell disease 2024 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Omega‐3 vs placebo

Frequency of sickle cell‐related complications · sickle cell disease

The review found no eligible studies for this question.

1 finding from 1 review

Antioxidant supplementation for sickle cell disease 2024 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Omega‐3 vs placebo

Haemoglobin status · sickle cell disease

It is very uncertain whether omega‐3 changes haemoglobin status compared with placebo (very low certainty).

1 finding from 1 review

Antioxidant supplementation for sickle cell disease 2024 · Cochrane Headline outcomes only
MD 0.36
1 study · 67 participants
Very low

Omega‐3 vs omega‐6

SAEs · people with multiple sclerosis

Omega‐3 showed no clear difference in SAEs (assessed as number of participants experiencing a SAE) compared with omega‐6 (low certainty).

1 finding from 1 review

Dietary interventions for multiple sclerosis‐related outcomes 2020 · Cochrane Headline outcomes only
RR 1.12 [0.38, 3.31]
4 studies · 230 participants
Low

Omega‐3 vs omega‐6

Relapse · people with multiple sclerosis

Omega‐3 showed no clear difference in relapse(assessed as number of participants experiencing relapse) compared with omega‐6 (low certainty).

1 finding from 1 review

Dietary interventions for multiple sclerosis‐related outcomes 2020 · Cochrane Headline outcomes only
RR 1.02 [0.62, 1.66]
2 studies · 129 participants
Low

Omega‐3 vs omega‐6

Change in validated disability scale ( · people with multiple sclerosis

1 finding from 1 review

Dietary interventions for multiple sclerosis‐related outcomes 2020 · Cochrane Headline outcomes only
no estimate extracted
3 studies · 166 participants
Low

Omega‐3 vs omega‐6

Global impression of deterioration (investigator defined global impression of deterioration) · people with multiple sclerosis

Omega‐3 showed no clear difference in global impression of deterioration (investigator defined global… compared with omega‐6 (moderate certainty).

1 finding from 1 review

Dietary interventions for multiple sclerosis‐related outcomes 2020 · Cochrane Headline outcomes only
RR 0.99 [0.51, 1.91]
1 study · 86 participants
Moderate

Omega‐3 vs omega‐6

MRI activity(assessed by new gadolinium‐enhancing lesions) · people with multiple sclerosis

1 finding from 1 review

Dietary interventions for multiple sclerosis‐related outcomes 2020 · Cochrane Headline outcomes only
no estimate extracted
1 study · 86 participants
Moderate

Omega‐3 vs placebo

Loss of patency by 12 months · Dialysis vascular access outcomes in AVF patients with ESKD

Omega‐3 fatty acids showed no clear difference in loss of patency: compared with placebo (moderate certainty).

1 finding from 1 review

Omega‐3 fatty acids for dialysis vascular access outcomes in patients with chronic kidney disease 2018 · Cochrane Headline outcomes only
RR 1.01 [0.84, 1.21]
1 study · 536 participants
Moderate

Omega‐3 vs placebo

Serious adverse events: cardiovascular events · dialysis vascular access outcomes in AVG patients with ESKD

It is very uncertain whether omega‐3 fatty acids changes serious adverse events: cardiovascular events compared with placebo (very low certainty).

1 finding from 1 review

Omega‐3 fatty acids for dialysis vascular access outcomes in patients with chronic kidney disease 2018 · Cochrane Headline outcomes only
no estimate extracted
4 studies · 261 participants
Very low

Omega‐3 vs placebo

Serious adverse events: major bleeding · dialysis vascular access outcomes in AVG patients with ESKD

It is very uncertain whether omega‐3 fatty acids changes serious adverse events: major bleeding compared with placebo (very low certainty).

1 finding from 1 review

Omega‐3 fatty acids for dialysis vascular access outcomes in patients with chronic kidney disease 2018 · Cochrane Headline outcomes only
RD 0.08
3 studies · 65 participants
Very low

Omega‐3 vs placebo

Serious adverse events: death · Dialysis vascular access outcomes in AVF patients with ESKD

Omega‐3 fatty acids showed no clear difference in serious adverse events: death compared with placebo (moderate certainty).

1 finding from 1 review

Omega‐3 fatty acids for dialysis vascular access outcomes in patients with chronic kidney disease 2018 · Cochrane Headline outcomes only
RD 0
1 study · 567 participants
Moderate

Omega‐3 vs placebo

Serious adverse events: hospitalisation · Dialysis vascular access outcomes in AVF patients with ESKD

Omega‐3 fatty acids showed no clear difference in serious adverse events: hospitalisation compared with placebo (low certainty).

1 finding from 1 review

Omega‐3 fatty acids for dialysis vascular access outcomes in patients with chronic kidney disease 2018 · Cochrane Headline outcomes only
RD 0
1 study · 567 participants
Low

Omega‐3 vs placebo

Serious adverse events: cardiovascular events · Dialysis vascular access outcomes in AVF patients with ESKD

The review found no eligible studies for this question.

1 finding from 1 review

Omega‐3 fatty acids for dialysis vascular access outcomes in patients with chronic kidney disease 2018 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Omega‐3 vs placebo

Serious adverse events: major bleeding · Dialysis vascular access outcomes in AVF patients with ESKD

The review found no eligible studies for this question.

1 finding from 1 review

Omega‐3 fatty acids for dialysis vascular access outcomes in patients with chronic kidney disease 2018 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Omega‐3 vs placebo

Loss of patency by 12 months · dialysis vascular access outcomes in AVG patients with ESKD

It is very uncertain whether omega‐3 fatty acids changes loss of patency by 6 months compared with placebo (very low certainty).

2 findings from 1 review

Omega‐3 fatty acids for dialysis vascular access outcomes in patients with chronic kidney disease 2018 · Cochrane Headline outcomes only
RR 0.91 [0.36, 2.28]
2 studies · 41 participants
Very low
Omega‐3 fatty acids for dialysis vascular access outcomes in patients with chronic kidney disease 2018 · Cochrane Headline outcomes only
RR 0.59 [0.27, 1.31]
2 studies · 220 participants
Very low